Data updated: Jun 28, 2026
IBD Clinical Trial Landscape
IBD is being studied across 105 clinical trials registered since 2008, with 24 programs currently active. The competitive pipeline includes 4 active Phase 3 trials, 9 active Phase 2 trials, and 7 active Phase 1 trials.
Top industry sponsors include Disc Medicine, Inc, iCell Gene Therapeutics, Parvus Therapeutics, Inc..
Trial activity
24 active / 105 total since 2008
Active by phase 4 Ph3 / 25 9 Ph2 / 24 7 Ph1 / 35 4 Ph4 / 21
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Disc Medicine, Inc 1 0 0
iCell Gene Therapeutics 1 0 0
Parvus Therapeutics, Inc. 1 0 0
Mirador Therapeutics, Inc. 1 0 0
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company 1 0 0
Resilience 1 0 0
Lmito Therapeutics Inc. 1 0 0
Eli Lilly 1 0 0
Benethera (Shaoxing) Biotechnology Co., Ltd. 1 0 0
Pharmacosmos A/S 0 5 0
AstraZeneca 0 0 3
Johnson & Johnson 0 3 0
Shield Therapeutics 0 3 0
How the field has grown
New-trial starts peaked in 2026 (10 registered); 2025 saw 9. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (8 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 4
2017 3
2018 6
2019 1
2020 3
2021 3
2022 2
2023 3
2024 5
2025 9
2026 10
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (1) 250
2017 (0) 0
2018 (1) 89
2019 (0) 0
2020 (2) 308
2021 (0) 0
2022 (0) 0
2023 (0) 0
2024 (1) 10
2025 (2) 118
2026 (1) 60
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT07582458 NOT YET RECRUITING
Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial)
Radboud University Medical Center n=60
NCT07047339 RECRUITING
Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis
Changhai Hospital n=120
NCT07043036 NOT YET RECRUITING
Randomized Controlled Trial Comparing Remote Patient Monitoring vs Standard Care in IBD Patients Initiating or Changing Advanced Therapy
Resilience n=116
NCT06604273 RECRUITING
Unravelling Intestinal Fibrosis in Ulcerative Colitis
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=10
NCT01022749 COMPLETED
Efficacy Safety Study of Flu Vaccine in Immunodepression Patients
Assistance Publique - Hôpitaux de Paris n=228
NCT01369355 COMPLETED
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Janssen Research & Development, LLC n=1,282
NCT04060303 COMPLETED
ENhanced Recovery in CHildren Undergoing Surgery
Northwestern University n=597
NCT03759288 TERMINATED
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
AstraZeneca n=89
NCT02680756 COMPLETED
Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
Shield Therapeutics n=250
NCT01340872 COMPLETED
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)
Shield Therapeutics n=128
NCT01352221 COMPLETED
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
Shield Therapeutics n=128
NCT01496053 COMPLETED
Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)
Oslo University Hospital n=100
NCT00620126 COMPLETED
The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis
University of Maryland, Baltimore n=47
NCT01692743 COMPLETED
Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
University of Maryland, Baltimore n=348
NCT03035058 WITHDRAWN
Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease
Takeda
NCT01369342 COMPLETED
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Janssen Research & Development, LLC n=640
NCT01369329 COMPLETED
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Janssen Research & Development, LLC n=769
NCT02771457 WITHDRAWN
Managing Infliximab Reinduction After Temporary Discontinuation of Drug
NYU Langone Health
NCT01428843 TERMINATED
Comparison of Ferrisat vs Placebo in Anemia Associated to Inflammatory Bowel Disease During Anti-TNF Therapy
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives n=60
NCT01599702 COMPLETED
Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease
Pharmacosmos A/S n=21
NCT01410435 COMPLETED
Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease
Pharmacosmos A/S n=39
NCT00810030 COMPLETED
FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR
Vifor Pharma n=484
NCT01017614 COMPLETED
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
Pharmacosmos A/S n=350
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only